FindTrial
Sign In

Seroprevalence of COVID-19 antibodies among patients living with hemophilia.

Seroprevalence of COVID-19 antibodies among patients living with hemophilia.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/06/043017
Enrollment
100
Registered
2022-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D65-D69- Coagulation defects, purpura and other hemorrhagic conditions

Interventions

Control Intervention1: NIL: NIL

Sponsors

Maulana Azad Medical College
Lead Sponsor
DR PRAVEEN BHARTI
Collaborator
DR ROHIT CHAWLA
Collaborator
DR SANDEEP GARG
Collaborator
DR SUNITA AGGARWAL
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with age greater than 13 years diagnosed with Hemophilia

Exclusion criteria

Exclusion criteria: NO EXCLUSION CRITERIA

Design outcomes

Primary

MeasureTime frame
To find out the seroprevalence of COVID-19 antibodies in the patients living with HemophiliaTimepoint: Baseline Cross Sectional—

Secondary

MeasureTime frame
To find out seroprevalence in previously confirmed cases of COVID-19 patients(detected positive in last 6 month) living with hemophilia.Timepoint: Baseline Cross Sectional;To find out the seroprevalence in asymptomatic patients living with hemophilia and to compare them with the general population (The latest seroprevalence published data at the time of completion of study).Timepoint: Baseline Cross Sectional—

Countries

India

Contacts

Public ContactDr Sunita Aggarwal

Maulana Azad Medical College & associated Lok Nayak Hospital

drsunita.mamc@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026